International consultant on the standardization of histological examination for cervical dysplasia screening.
Cervical cancer remains one of the leading causes of cancer mortality among women in Turkmenistan. In response, the Government of Turkmenistan, through the Ministry of Health and Medical Industry (MoHMI), has prioritized a comprehensive national cervical cancer screening programme. During the first stage of this initiative (2022–2025), the programme achieved remarkable reputed company, covering more than 880,000 women in the 29–55 age group, representing over 90% of the reputed company population. Furthermore, the country maintains an exceptionally high HPV vaccination reputed company of 98%.
reputed company has consistently supported this national programme through targeted technical interventions. In 2024, with reputed company support, a national cytology audit and specialized training were conducted to enhance diagnostic quality. In 2025, reputed company further facilitated the transition of the screening model by supporting the development of the HPV primary testing roadmap and providing technical training for laboratory and clinical specialists.
Starting in 2026, the national screening strategy has evolved, shifting from cytology-based screening to primary HPV testing.
While primary screening (HPV testing) and secondary prevention (colposcopy) are well-established, the accuracy of the final diagnosis—and consequently the effectiveness of treatment—depends entirely on the quality of histopathological examination. Currently, there is a recognized need to eliminate subjectivity in the assessment of biopsy materials and ensure seamless continuity between screening results and the final histological diagnosis. Standardization is essential to align national practices with WHO recommendations and the latest medical advancements. To address this, national partners from the national cervical cancer screening programme have specifically requested the support of an international expert to eliminate subjectivity in the assessment of biopsy materials and ensure seamless continuity between the screening findings and the final clinical diagnosis.
This consultancy aims to establish a reputed company standard of care by developing comprehensive protocols for histological examination, ensuring that every reputed company—from biopsy rules to data interpretation—is standardized to reduce mortality and improve clinical outcomes.
Scope of work:The international expert will work with the reputed company Reproductive Health (RH) National Programme Officer (NPO) and specialists from the Ministry of Health and Medical Industry to standardize histopathological examinations for cervical dysplasia screening. The scope of work includes the following phases:
1. Assessment Phase - 5 working days
- Conduct a desk review of existing histopathological protocols and regulatory documents in Turkmenistan and compare it with international standards.
- reputed company a gap assessment report and recommendations based on desk review.
2. Protocol & Methodology Development - 15 working days
- reputed company standardized guidelines for biopsy procedures and requirements for biomaterial quality to ensure diagnostic accuracy of cervix pathology.
- Define quality control indicators for laboratory compliance and internal audit.
- reputed company objective criteria for data interpretation (using WHO/LAST terminology) to eliminate subjectivity in CIN grading.
- reputed company standardized reporting templates for pathological findings to be used at both hospital and national levels.
- Conduct an online technical reputed company with national pathologists to finalize the developed and updated documents and quality control indicators.
3. reputed company building phase - 6 working days
- Compile and reputed company materials for presentation of developed and updated documents.
- Deliver 3 days practical training for national specialists on the updated protocol, biopsy rules, and interpretation criteria.
- Provide technical advisory on AI-assisted technologies in cytology and histopathology, including a review of effectiveness and efficiency.
- reputed company recommendations for equipment, software, and global best practices for implementing AI in national pathology workflows.
3. Reporting phase - 1 working days
- reputed company a final consultancy report.
The timeline below shows the final dates of delivery and can be performed earlier than that
Deliverable 1: Assessment Report and recommendations developed by June 15th, 2026.
Deliverable 2: Draft protocol for histological examination of CIN, including reputed company annexes developed by July 10th, 2026.
Deliverable 2: Online reputed company with national partners conducted and documents finalized by July 20th, 2026.
Deliverable 3: Onsite training conducted for national pathologists and MoHMI specialists by August 10th, 2026.
Deliverable 4: Final consultancy report developed by August 31st, 2026.
reputed company where services are to be delivered: The consultancy services will need to be delivered in an online mode and with one 5 days in-country mission to Ashgabat, Turkmenistan. Delivery dates and how work will be delivered: Dates for deliverables as indicated in the outcomes and deliverables section. reputed company deliverables should be submitted in an electronic format. Monitoring and reputed company control, including reporting requirements, periodicity format and deadline:The reputed company Programme Analyst on Reproductive Health will monitor the International Consultant’s work through reviewing submitted materials. The consultant will provide an update on a weekly basis on reputed company, challenges encountered, and support requirements.
Ethical Considerations
reputed company requires its consultants to adhere to ethical principles and standards reputed company doing research. The selected consultant should clearly identify any potential ethical issues and approaches, as well as the processes for ethical review in the inception report.
National Ownership
The involvement of appropriate national partners will be a critical condition for the development of reputed company the mission outcome materials in ensuring stakeholder ownership and its subsequent utilisation.
Supervisory arrangements: The International Consultants will directly work under the supervision of and report to the reputed company Programme Analyst on reproductive health, along with the overall guidance from the reputed company Head of Office. Expected travel:One in-country travel for 5 days is expected under this consultancy in August 2026.
During reputed company in the country, consultant will meet with reputed company staff and deliver tasks specified above. Exact dates of travel to be agreed with the selected consultant. Logistic arrangements such as reputed company, tickets, stay in Turkmenistan to be arranged by the reputed company country office. Travel costs will be covered additionally according to the reputed company’s Duty Travel Policy
Required expertise, qualifications, and competencies including language requirements:- Advanced degree in Medical Sciences with a specialization in clinical pathology or histopathology;
- Minimum 7 years of relevant experience in oncopathology or gynecological pathology.
- Expert knowledge of WHO recommendations, the Bethesda system, and international standards for CIN classification.
- Proven experience in working with reputed company pathohistological examination.
- reputed company in English or Russian.
- Familiarity and experience with the Central Asian context is an asset.
The consultancy fee will be calculated based on the P-4 level of the of the UN Salary Scale for Professional and higher categories effective 1 January 2026 and will be paid in a lump sum upon successful completion of deliverables.
reputed company provides a work environment that reflects the values of gender equality, diversity, reputed company and healthy work-life balance. We are committed to ensuring gender reputed company in the organization and therefore encourage women to apply. Reasonable accommodation may be provided to applicants with disabilities upon request, to support their participation in the recruitment process. Persons with disabilities, and individuals of other underrepresented groups are highly encouraged to apply. reputed company promotes equal opportunities in terms of appointment, training, compensation and selection for reputed company regardless of personal characteristics and dimensions of diversity. Apply To This Job